{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:26:43Z","timestamp":1789097203228,"version":"build-2803163510"},"reference-count":115,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.drudis.2024.103878","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T21:34:51Z","timestamp":1704836091000},"page":"103878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Recent discoveries of the role of histone modifications and related inhibitors in pathological cardiac hypertrophy"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0809-5628","authenticated-orcid":false,"given":"Ke-Jia","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hang","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.103878_b0005","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1161\/CIRCRESAHA.119.313569","article-title":"Novel therapies for prevention and early treatment of cardiomyopathies: now and in the future","volume":"124","author":"Repetti","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.drudis.2024.103878_b0010","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMra0902923","article-title":"Inherited cardiomyopathies","volume":"364","author":"Watkins","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.103878_b0015","article-title":"Inherited cardiomyopathies","volume":"365","author":"Miles","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2024.103878_b0020","doi-asserted-by":"crossref","first-page":"8721","DOI":"10.3390\/ijms22168721","article-title":"The emerging role of epigenetics in therapeutic targeting of cardiomyopathies","volume":"22","author":"Pagiatakis","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.103878_b0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41569-022-00806-6","article-title":"Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential","volume":"20","author":"Martin","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.drudis.2024.103878_b0030","doi-asserted-by":"crossref","first-page":"R546","DOI":"10.1016\/j.cub.2004.07.007","article-title":"Histones and histone modifications","volume":"14","author":"Peterson","year":"2004","journal-title":"Curr Biol"},{"key":"10.1016\/j.drudis.2024.103878_b0035","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.prp.2017.06.013","article-title":"Histone modifications: a review about the presence of this epigenetic phenomenon in carcinogenesis","volume":"213","author":"Chrun","year":"2017","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.drudis.2024.103878_b0040","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/path.4234","article-title":"Epigenetics and chromatin remodeling in adult cardiomyopathy","volume":"231","author":"Mahmoud","year":"2013","journal-title":"J Pathol"},{"key":"10.1016\/j.drudis.2024.103878_b0045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: a dynamic mark in health, disease and inheritance","volume":"13","author":"Greer","year":"2012","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.drudis.2024.103878_b0050","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/jhg.2013.66","article-title":"Histone modifications for human epigenome analysis","volume":"58","author":"Kimura","year":"2013","journal-title":"J Hum Genet"},{"key":"10.1016\/j.drudis.2024.103878_b0055","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/CIRCRESAHA.118.312497","article-title":"Epigenetic modifications in cardiovascular aging and diseases","volume":"123","author":"Zhang","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.drudis.2024.103878_b0060","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.272.5260.408","article-title":"A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p","volume":"272","author":"Taunton","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.drudis.2024.103878_b0065","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.103878_b0070","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1101\/gad.1563807","article-title":"Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility","volume":"21","author":"Montgomery","year":"2007","journal-title":"Genes Dev"},{"key":"10.1016\/j.drudis.2024.103878_b0075","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1172\/JCI35847","article-title":"Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice","volume":"118","author":"Montgomery","year":"2008","journal-title":"J Clin Investig"},{"key":"10.1016\/j.drudis.2024.103878_b0080","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.drudis.2024.103878_b0085","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/cvr\/cvq376","article-title":"Sirt1 acts in association with PPAR\u03b1 to protect the heart from hypertrophy, metabolic dysregulation, and inflammation","volume":"90","author":"Planavila","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.drudis.2024.103878_b0090","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.117.028728","article-title":"SIRT2 acts as a cardioprotective deacetylase in pathological cardiac hypertrophy","volume":"136","author":"Tang","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2024.103878_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-015-0493-6","article-title":"SIRT3 deficiency impairs mitochondrial and contractile function in the heart","volume":"110","author":"Koentges","year":"2015","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.drudis.2024.103878_b0100","first-page":"1389","article-title":"SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity","volume":"38","author":"Luo","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.drudis.2024.103878_b0105","doi-asserted-by":"crossref","first-page":"19767","DOI":"10.1074\/jbc.M117.809897","article-title":"Sirtuin 5 is required for mouse survival in response to cardiac pressure overload","volume":"292","author":"Hershberger","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2024.103878_b0110","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/nm.2961","article-title":"The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun","volume":"18","author":"Sundaresan","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2024.103878_b0115","doi-asserted-by":"crossref","first-page":"9115","DOI":"10.1093\/nar\/gkz648","article-title":"SIRT6 transcriptionally regulates global protein synthesis through transcription factor Sp1 independent of its deacetylase activity","volume":"47","author":"Ravi","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2024.103878_b0120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/HYPERTENSIONAHA.119.13357","article-title":"Cardiomyocyte Sirt (Sirtuin) 7 ameliorates stress-induced cardiac hypertrophy by interacting with and deacetylating GATA4","volume":"75","author":"Yamamura","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2024.103878_b0125","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1111\/febs.15895","article-title":"HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes","volume":"289","author":"N\u00fa\u00f1ez-\u00c1lvarez","year":"2022","journal-title":"FEBS J"},{"key":"10.1016\/j.drudis.2024.103878_b0130","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.bbrc.2018.04.090","article-title":"HDAC11 deletion reduces fructose-induced cardiac dyslipidemia, apoptosis and inflammation by attenuating oxidative stress injury","volume":"503","author":"Fan","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2024.103878_b0135","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00210-019-01749-5","article-title":"Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production","volume":"393","author":"Yoon","year":"2020","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.drudis.2024.103878_b0140","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.112.103176","article-title":"Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid","volume":"126","author":"Zhao","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2024.103878_b0145","doi-asserted-by":"crossref","first-page":"28930","DOI":"10.1074\/jbc.M303113200","article-title":"Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors","volume":"278","author":"Antos","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2024.103878_b0150","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI19137","article-title":"Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop","volume":"112","author":"Kook","year":"2003","journal-title":"J Clin Investig"},{"key":"10.1016\/j.drudis.2024.103878_b0155","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/sj.onc.1210602","article-title":"Hat1: the emerging cellular roles of a type B histone acetyltransferase","volume":"26","author":"Parthun","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2024.103878_b0160","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1038\/sj.onc.1210619","article-title":"Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design","volume":"26","author":"Hodawadekar","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2024.103878_b0165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.yjmcc.2021.06.011","article-title":"Function of histone methylation and acetylation modifiers in cardiac hypertrophy","volume":"159","author":"Qin","year":"2021","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.drudis.2024.103878_b0170","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bbrc.2014.04.112","article-title":"The histone acetyltransferase MOF overexpression blunts cardiac hypertrophy by targeting ROS in mice","volume":"448","author":"Qiao","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2024.103878_b0175","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ydbio.2015.04.011","article-title":"Mesodermal expression of Moz is necessary for cardiac septum development","volume":"403","author":"Vanyai","year":"2015","journal-title":"Dev Biol"},{"key":"10.1016\/j.drudis.2024.103878_b0180","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCHEARTFAILURE.114.001193","article-title":"Epigenetic mechanisms in heart failure pathogenesis","volume":"7","author":"Di Salvo","year":"2014","journal-title":"Circulat Heart Fail"},{"key":"10.1016\/j.drudis.2024.103878_b0185","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0092-8674(00)81165-4","article-title":"Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300","volume":"93","author":"Yao","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2024.103878_b0190","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.107.760488","article-title":"Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300","volume":"118","author":"Wei","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2024.103878_b0195","first-page":"868","article-title":"The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats","volume":"118","author":"Morimoto","year":"2008","journal-title":"J Clin Investig"},{"key":"10.1016\/j.drudis.2024.103878_b0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.yjmcc.2019.04.012","article-title":"Epigenetic therapies in heart failure","volume":"130","author":"Alexanian","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.drudis.2024.103878_b0205","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1074\/jbc.M110.163865","article-title":"HDAC3-dependent reversible lysine acetylation of cardiac myosin heavy chain isoforms modulates their enzymatic and motor activity","volume":"286","author":"Samant","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2024.103878_b0210","doi-asserted-by":"crossref","first-page":"e138687","DOI":"10.1172\/jci.insight.138687","article-title":"BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy","volume":"5","author":"Antolic","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.drudis.2024.103878_b0215","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1161\/CIRCULATIONAHA.120.047239","article-title":"Epigenetic reader BRD4 (bromodomain-containing protein 4) governs nucleus-encoded mitochondrial transcriptome to regulate cardiac function","volume":"142","author":"Kim","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2024.103878_b0220","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2013.07.013","article-title":"BET bromodomains mediate transcriptional pause release in heart failure","volume":"154","author":"Anand","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2024.103878_b0225","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yjmcc.2018.12.002","article-title":"Inhibition of BRD4 attenuates transverse aortic constriction-and TGF-\u03b2-induced endothelial-mesenchymal transition and cardiac fibrosis","volume":"127","author":"Song","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.drudis.2024.103878_b0230","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2147\/VHRM.S287082","article-title":"Epigenetic therapies for heart failure: current insights and future potential","volume":"17","author":"Napoli","year":"2021","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.drudis.2024.103878_b0235","doi-asserted-by":"crossref","first-page":"19754","DOI":"10.1073\/pnas.1310658110","article-title":"RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain","volume":"110","author":"Picaud","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.drudis.2024.103878_b0240","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1039\/C5SC02321A","article-title":"An iridium (III)-based irreversible protein\u2013protein interaction inhibitor of BRD4 as a potent anticancer agent","volume":"6","author":"Zhong","year":"2015","journal-title":"Chem Sci"},{"key":"10.1016\/j.drudis.2024.103878_b0245","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019521","article-title":"Histone modifications and cancer","volume":"8","author":"Audia","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.drudis.2024.103878_b0250","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.athoracsur.2017.04.046","article-title":"Histone modification is correlated with reverse left ventricular remodeling in nonischemic dilated cardiomyopathy","volume":"104","author":"Ito","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.drudis.2024.103878_b0255","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1161\/CIRCULATIONAHA.117.028561","article-title":"Histone methyltransferase G9a is required for cardiomyocyte homeostasis and hypertrophy","volume":"136","author":"Papait","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2024.103878_b0260","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1172\/JCI88353","article-title":"The H3K9 dimethyltransferases EHMT1\/2 protect against pathological cardiac hypertrophy","volume":"127","author":"Thienpont","year":"2017","journal-title":"J Clin Investig"},{"key":"10.1016\/j.drudis.2024.103878_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-07173-2","article-title":"Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2024.103878_b0270","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2119\/molmed.2017.00012","article-title":"The histone methyltransferase mixed lineage leukemia (MLL) 3 may play a potential role in clinical dilated cardiomyopathy","volume":"23","author":"Jiang","year":"2017","journal-title":"Mol Med"},{"key":"10.1016\/j.drudis.2024.103878_b0275","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.phrs.2016.01.026","article-title":"Jumonji histone demethylases as emerging therapeutic targets","volume":"105","author":"Park","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2024.103878_b0280","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI61084","article-title":"HDAC4 controls histone methylation in response to elevated cardiac load","volume":"123","author":"Hohl","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2024.103878_b0285","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1172\/JCI46277","article-title":"The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice","volume":"121","author":"Zhang","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2024.103878_b0290","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/10799893.2020.1734819","article-title":"Inhibition of histone demethylase JMJD1C attenuates cardiac hypertrophy and fibrosis induced by angiotensin II","volume":"40","author":"Zhang","year":"2020","journal-title":"J Recept Signal Transduct"},{"key":"10.1016\/j.drudis.2024.103878_b0295","doi-asserted-by":"crossref","first-page":"13275","DOI":"10.1002\/ange.201807305","article-title":"Selective inhibition of lysine-specific demethylase 5A (KDM5A) using a rhodium (III) complex for triple-negative breast cancer therapy","volume":"130","author":"Yang","year":"2018","journal-title":"Angew Chem"},{"key":"10.1016\/j.drudis.2024.103878_b0300","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1101\/gad.2018511","article-title":"DOT1L regulates dystrophin expression and is critical for cardiac function","volume":"25","author":"Nguyen","year":"2011","journal-title":"Genes Dev"},{"key":"10.1016\/j.drudis.2024.103878_b0305","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.103878_b0310","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nrg3603","article-title":"A new world of Polycombs: unexpected partnerships and emerging functions","volume":"14","author":"Schwartz","year":"2013","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.drudis.2024.103878_b0315","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ng.1068","article-title":"Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis","volume":"44","author":"Delgado-Olgu\u00edn","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2024.103878_b0320","first-page":"9174926","article-title":"EZH2 inhibition ameliorates transverse aortic constriction\u2013induced pulmonary arterial hypertension in mice","volume":"2018","author":"Shi","year":"2018","journal-title":"Can Respir J"},{"key":"10.1016\/j.drudis.2024.103878_b0325","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/CIRCRESAHA.111.263665","article-title":"Neurohormonal regulation of cardiac histone deacetylase 5 nuclear localization by phosphorylation-dependent and phosphorylation-independent mechanisms","volume":"110","author":"Haworth","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.drudis.2024.103878_b0330","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.1093\/nar\/gkt500","article-title":"Nuclear CaMKII enhances histone H3 phosphorylation and remodels chromatin during cardiac hypertrophy","volume":"41","author":"Awad","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2024.103878_b0335","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0022-2828(78)90393-0","article-title":"Studies of nuclear proteins in the heart of the cardiomyopathic Syrian hamster\u2014phosphorylation of histones","volume":"10","author":"Liew","year":"1978","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.drudis.2024.103878_b0340","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1161\/CIRCULATIONAHA.110.003665","article-title":"Casein kinase-2\u03b11 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart","volume":"123","author":"Eom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2024.103878_b0345","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.drudis.2024.103878_b0350","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fgene.2018.00336","article-title":"Emergence of members of TRAF and DUB of ubiquitin proteasome system in the regulation of hypertrophic cardiomyopathy","volume":"9","author":"Gupta","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.drudis.2024.103878_b0355","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nature02985","article-title":"Role of histone H2A ubiquitination in Polycomb silencing","volume":"431","author":"Wang","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.103878_b0360","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1111\/jcmm.13669","article-title":"The role of K63-linked polyubiquitination in cardiac hypertrophy","volume":"22","author":"Yan","year":"2018","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.drudis.2024.103878_b0365","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1161\/HYPERTENSIONAHA.116.07392","article-title":"Ubiquitin-specific protease 4 is an endogenous negative regulator of pathological cardiac hypertrophy","volume":"67","author":"He","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2024.103878_b0370","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/HYPERTENSIONAHA.116.07562","article-title":"Novel protective role for ubiquitin-specific protease 18 in pathological cardiac remodeling","volume":"68","author":"Ying","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2024.103878_b0375","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.bbrc.2016.08.100","article-title":"Ubiquitin-specific protease 14 regulates cardiac hypertrophy progression by increasing GSK-3\u03b2 phosphorylation","volume":"478","author":"Liu","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2024.103878_b0380","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1172\/JCI200422220","article-title":"Atrogin-1\/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex","volume":"114","author":"Li","year":"2004","journal-title":"J Clin Investig"},{"key":"10.1016\/j.drudis.2024.103878_b0385","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCULATIONAHA.121.054827","article-title":"Targeting E3 ubiquitin ligase WWP1 prevents cardiac hypertrophy through destabilizing DVL2 via inhibition of K27-linked ubiquitination","volume":"144","author":"Zhao","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2024.103878_b0390","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/JME-15-0283","article-title":"MuRF1 mono-ubiquitinates TR\u03b1 to inhibit T3-induced cardiac hypertrophy in vivo","volume":"56","author":"Wadosky","year":"2016","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.drudis.2024.103878_b0395","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCHEARTFAILURE.113.000713","article-title":"Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A","volume":"7","author":"Maejima","year":"2014","journal-title":"Circulat Heart Fail"},{"key":"10.1016\/j.drudis.2024.103878_b0400","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nrm1200","article-title":"Nuclear and unclear functions of SUMO","volume":"4","author":"Seeler","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.drudis.2024.103878_b0405","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/CIRCRESAHA.110.220491","article-title":"Sumoylation and regulation of cardiac gene expression","volume":"107","author":"Wang","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.drudis.2024.103878_b0410","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCRESAHA.115.308268","article-title":"UBC9-mediated sumoylation favorably impacts cardiac function in compromised hearts","volume":"118","author":"Gupta","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.drudis.2024.103878_b0415","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.dib.2017.11.040","article-title":"Data supporting the angiotensin II activates MEL18 to deSUMOylate HSF2 for hypertension-related heart failure","volume":"16","author":"Huang","year":"2018","journal-title":"Data Brief"},{"key":"10.1016\/j.drudis.2024.103878_b0420","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/hr.2011.228","article-title":"Myofibrillogenesis regulator 1 induces hypertrophy by promoting sarcomere organization in neonatal rat cardiomyocytes","volume":"35","author":"Wang","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1016\/j.drudis.2024.103878_b0425","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tibs.2008.09.004","article-title":"The COP9 signalosome: more than a protease","volume":"33","author":"Wei","year":"2008","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.drudis.2024.103878_b0430","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCRESAHA.110.230607","article-title":"Perturbation of cullin deneddylation via conditional Csn8 ablation impairs the ubiquitin\u2013proteasome system and causes cardiomyocyte necrosis and dilated cardiomyopathy in mice","volume":"108","author":"Su","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.drudis.2024.103878_b0435","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.bbrc.2004.09.156","article-title":"ZAK re-programs atrial natriuretic factor expression and induces hypertrophic growth in H9c2 cardiomyoblast cells","volume":"324","author":"Huang","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2024.103878_b0440","doi-asserted-by":"crossref","first-page":"7855","DOI":"10.1002\/jcb.27199","article-title":"ER\u03b2 targets ZAK and attenuates cellular hypertrophy via SUMO-1 modification in H9c2 cells","volume":"119","author":"Pai","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.drudis.2024.103878_b0445","doi-asserted-by":"crossref","first-page":"20164","DOI":"10.1073\/pnas.1315155110","article-title":"Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy","volume":"110","author":"Papait","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2024.103878_b0450","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/labinvest.2011.92","article-title":"Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+-ATPase and calcium homeostasis in cardiac myocytes","volume":"91","author":"Kao","year":"2011","journal-title":"Lab Invest"},{"key":"10.1016\/j.drudis.2024.103878_b0455","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cvr\/cvq066","article-title":"Metformin attenuates cardiac fibrosis by inhibiting the TGF\u03b21\u2013Smad3 signalling pathway","volume":"87","author":"Xiao","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.drudis.2024.103878_b0460","doi-asserted-by":"crossref","first-page":"8805","DOI":"10.1038\/s41598-018-27181-y","article-title":"Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes","volume":"8","author":"Nishitani","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2024.103878_b0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-020-01359-z","article-title":"Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors and ketogenesis: the good and the bad","volume":"20","author":"Ekanayake","year":"2020","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.drudis.2024.103878_b0470","first-page":"156","article-title":"Fatty acids and epigenetics","volume":"17","author":"Burdge","year":"2014","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.drudis.2024.103878_b0475","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/CIRCULATIONAHA.115.019949","article-title":"Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL randomized clinical trial","volume":"134","author":"Heydari","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2024.103878_b0480","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/cvr\/cvr250","article-title":"Homocysteine promotes human endothelial cell dysfunction via site-specific epigenetic regulation of p66shc","volume":"92","author":"Kim","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.drudis.2024.103878_b0485","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.923014","article-title":"Epi-drugs in heart failure","volume":"9","author":"Gorica","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.drudis.2024.103878_b0490","doi-asserted-by":"crossref","first-page":"e28534","DOI":"10.1371\/journal.pone.0028534","article-title":"Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages","volume":"6","author":"Feig","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2024.103878_b0495","doi-asserted-by":"crossref","first-page":"26484","DOI":"10.1074\/jbc.M803686200","article-title":"Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy","volume":"283","author":"Trivedi","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2024.103878_b0500","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1128\/MCB.24.19.8467-8476.2004","article-title":"Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development","volume":"24","author":"Chang","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.drudis.2024.103878_b0505","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0092-8674(02)00861-9","article-title":"Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy","volume":"110","author":"Zhang","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2024.103878_b0510","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1074\/jbc.M211762200","article-title":"The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity","volume":"278","author":"Gusterson","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2024.103878_b0515","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/CIRCRESAHA.111.252205","article-title":"Polycomb repressive complex 2 regulates normal development of the mouse heart","volume":"110","author":"He","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.drudis.2024.103878_b0520","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/ATVBAHA.115.305230","article-title":"Histone methyltransferase SET1 mediates angiotensin II-induced endothelin-1 transcription and cardiac hypertrophy in mice","volume":"35","author":"Yu","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.drudis.2024.103878_b0525","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/CIRCULATIONAHA.112.102780","article-title":"CKIP-1 inhibits cardiac hypertrophy by regulating class II histone deacetylase phosphorylation through recruiting PP2A","volume":"126","author":"Ling","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2024.103878_b0530","doi-asserted-by":"crossref","first-page":"11267","DOI":"10.1038\/ncomms11267","article-title":"The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling","volume":"7","author":"Ji","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2024.103878_b0535","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4196\/kjpp.2016.20.5.477","article-title":"Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats","volume":"20","author":"Lee","year":"2016","journal-title":"Korean J Physiol Pharmacol"},{"key":"10.1016\/j.drudis.2024.103878_b0540","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1139\/cjpp-2016-0542","article-title":"Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy","volume":"95","author":"Raghunathan","year":"2017","journal-title":"Can J Physiol Pharmacol"},{"issue":"19","key":"10.1016\/j.drudis.2024.103878_b0545","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.121.054262","article-title":"HDAC inhibition in the heart: erasing hidden fibrosis","volume":"143","author":"G","year":"2021","journal-title":"J Circulat"},{"key":"10.1016\/j.drudis.2024.103878_b0550","doi-asserted-by":"crossref","first-page":"659","DOI":"10.18632\/aging.100203","article-title":"Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes","volume":"2","author":"Karagiannis","year":"2010","journal-title":"Aging"},{"key":"10.1016\/j.drudis.2024.103878_b0555","doi-asserted-by":"crossref","first-page":"8139","DOI":"10.1111\/jcmm.14684","article-title":"Sodium butyrate attenuates angiotensin II-induced cardiac hypertrophy by inhibiting COX2\/PGE2 pathway via a HDAC5\/HDAC6-dependent mechanism","volume":"23","author":"Zhang","year":"2019","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.drudis.2024.103878_b0560","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1038\/s41467-018-07173-2","article-title":"Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2024.103878_b0565","doi-asserted-by":"crossref","first-page":"e136488","DOI":"10.1172\/JCI136488","article-title":"Targeting the histone demethylase LSD1 prevents cardiomyopathy in a mouse model of laminopathy","volume":"131","author":"Guenantin","year":"2021","journal-title":"J Clin Investig"},{"key":"10.1016\/j.drudis.2024.103878_b0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01199-x","article-title":"Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study","volume":"20","author":"Nicholls","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.drudis.2024.103878_b0575","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.yjmcc.2013.07.017","article-title":"BET acetyl-lysine binding proteins control pathological cardiac hypertrophy","volume":"63","author":"Spiltoir","year":"2013","journal-title":"J Mol Cell Cardiol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:09:32Z","timestamp":1761224972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1359644624000035"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2024.103878","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent discoveries of the role of histone modifications and related inhibitors in pathological cardiac hypertrophy","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.103878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103878"}}